Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-11-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于监事辞职及补选监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor and the nomination of a new supervisor candidate. It includes details about the resignation, the legal implications, and the nomination process for the replacement. There are no financial statements, earnings data, or regulatory certifications. The content focuses on changes in the company's supervisory board, which falls under management or board information disclosures. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2023-11-27 Chinese
监事会关于回购注销部分限制性股票及注销部分股票期权的审核意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board opinion on the repurchase and cancellation of restricted shares and stock options. It discusses the approval of repurchasing and canceling shares and stock options due to employees leaving the company and no longer meeting incentive plan requirements. The document references relevant laws and company regulations and mentions that the matter will be submitted to a shareholders' meeting for approval. This is a detailed announcement related to share repurchase and cancellation activities, which fits the category of Transaction in Own Shares (POS). The document is short (985 characters) but contains substantive content about the transaction itself, not just an announcement of a report or a certification. Therefore, it is classified as POS with high confidence.
2023-11-27 Chinese
关于注销部分2022年限制性股票与股票期权激励计划激励对象已获授但尚未行权股票期权的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Changchun High-tech Industry (Group) Co., Ltd. regarding the cancellation of certain stock options granted under the 2022 restricted stock and stock option incentive plan. It details the board and supervisory meetings approving the cancellation, the reasons for cancellation (employees leaving the company), the number of stock options cancelled, and the legal and independent director opinions supporting the action. The document is focused on corporate governance and management decisions related to stock option incentives, not a financial report or earnings release. It is not a full annual or interim report, nor a proxy or voting result announcement. The content fits best with a management or board information announcement about changes in stock incentive plans and related approvals. Therefore, the classification is Board/Management Information (MANG). The document length (5496 characters) and detailed procedural content support this classification with high confidence.
2023-11-27 Chinese
关于控股子公司GS1-144片临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (677 characters) from a company about its controlling subsidiary receiving approval from the National Medical Products Administration for a clinical trial application. It does not contain financial data, management discussion, or detailed report content. It is an official announcement about a regulatory approval related to clinical trials, not a financial report or management report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-11-27 Chinese
第十届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 30th meeting of the 10th Board of Directors of Changchun High-tech Industry (Group) Co., Ltd. It includes voting results on various proposals such as stock repurchase and cancellation, amendments to the Articles of Association, and revisions to the Board Meeting Rules and Independent Director System. The document also contains detailed amendments to governance documents and rules, indicating it is focused on board and management governance matters. There is no financial data or earnings information, nor is it a transcript or presentation. It is not a notice of voting results from a shareholder meeting but rather a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2023-11-27 Chinese
关于部分董事、监事、高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the purchase of company shares by some of the company's directors, supervisors, and senior management personnel. It details the names, positions, share quantities before and after the purchase, purchase dates, prices, and compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion of financial results. The content fits the definition of a Director's Dealing report, which is a report of personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on insider share transactions, confirming it is not a full financial report or other type of filing.
2023-11-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.